Abstract
Romosozumab (EVENITY (TM)) is a humanised monoclonal antibody against sclerostin being developed by Amgen and UCB for the treatment of osteoporosis. O......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
